within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M02A_TopicalProductsForJointAndMuscularPain.M02AA12_Naproxen;

model Naproxen
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.95,
    Cl = 3.3333333333333334e-08,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013333333333333333,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Naproxen</td></tr><tr><td>ATC code:</td><td>M02AA12</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.12</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, fever, swelling, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. It is widely approved and in use globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects, mixed sex, single oral dose.</p><h4>References</h4><ol><li><p>Välitalo, P, et al., &amp; Kokki, H (2012). Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children. <i>Journal of clinical pharmacology</i> 52(10) 1516–1526. DOI:<a href=\"https://doi.org/10.1177/0091270011418658\">10.1177/0091270011418658</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22067196/\">https://pubmed.ncbi.nlm.nih.gov/22067196</a></p></li><li><p>Mendell, J, et al., &amp; Samama, MM (2013). The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. <i>Journal of cardiovascular pharmacology</i> 62(2) 212–221. DOI:<a href=\"https://doi.org/10.1097/FJC.0b013e3182970991\">10.1097/FJC.0b013e3182970991</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23615159/\">https://pubmed.ncbi.nlm.nih.gov/23615159</a></p></li><li><p>Kubitza, D, et al., &amp; Zuehlsdorf, M (2007). Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. <i>British journal of clinical pharmacology</i> 63(4) 469–476. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2006.02776.x\">10.1111/j.1365-2125.2006.02776.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17100983/\">https://pubmed.ncbi.nlm.nih.gov/17100983</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M02AA12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Naproxen;
